HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma

BACKGROUND AND AIMS: Orthotopic liver transplantation (OLT) can be an effective treatment option for certain patients with early stage hepatocellular carcinoma (HCC) meeting Milan, UCSF, or Hangzhou criteria. However, HCC recurrence rates post-OLT range from 20 to 40 %, with limited follow-up option...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Feng, Higgs, Brandon W., Huang, Jiaqi, Morehouse, Chris, Zhu, Wei, Yao, Xin, Brohawn, Philip, Xiao, Zhan, Sebastian, Yinong, Liu, Zheng, Xia, Yun, Shen, Dong, Kuziora, Mike, Dong, Zhengwei, Han, Hulin, Gu, Yi, Gu, Jianren, Xia, Qiang, Yao, Yihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676172/
https://www.ncbi.nlm.nih.gov/pubmed/26653219
http://dx.doi.org/10.1186/s12967-015-0743-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676172/
https://www.ncbi.nlm.nih.gov/pubmed/26653219
http://dx.doi.org/10.1186/s12967-015-0743-2

Ejemplares similares